Cholinesterase Activity and DeliriUm During Critical Illness Study

Cognitive Impairment Clinical Trial

— CADUCeuS  

Official title:

Cholinesterase Activity and Delirium During Critical Illness Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03098472
• Other study ID #: CADUCeuS
• Status: Completed
• Start date: May 8, 2017
• Est. completion date: February 1, 2021

Study information

• Verified date: March 2022
• Source: Vanderbilt University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Delirium is a syndrome of acute brain dysfunction involving attention and cognition that affects up to half of older hospitalized patients and 50%-75% of critically ill ICU patients, such that millions of patients worldwide experience this acute threat to their health and well being every year. One-third to half of critical illness survivors struggle with a dementia-like disorder similar in severity to moderate-to-severe traumatic brain injury or Alzheimer's Disease, and the only proven risk factor that is potentially modifiable is delirium in the ICU. Despite the frequency and impact of delirium in the ICU, little is known regarding the biological mechanisms that lead to this form of organ dysfunction during critical illness. A widely held hypothesis proposes that inflammation is regulated by the cholinergic system, and that this interaction plays a pivotal role whether delirium developments in the setting of acute illness. Acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) are enzymes that hydrolyze the neurotransmitter acetylcholine. Changes in the activity of these enzymes, which can be measured in whole blood, reflect altered regulation of circulating acetylcholine. AChE and BuChE activities have promise as both predictors of delirium (when found to be low at admission) and biomarkers of delirium (when low during serial measurement). Neither of these biomarkers, however, have been studied in the ICU setting where delirium risk is the highest. The current investigation, therefore will be the first to determine the validity of circulating AChE and BuChE activities as biomarkers of delirium during critical illness and subsequent cognitive impairment after discharge. This study will measure whole blood AChE and butyrylcholinesterase BuChE activities within the framework of the ICU Delirium and Cognitive Impairment Study Group's ongoing clinical trials in critically ill patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 279
• Est. completion date: February 1, 2021
• Est. primary completion date: January 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• English-speaking adults (>18 years of age) treated for acute respiratory failure (with mechanical ventilation or non-invasive positive pressure ventilation [NIPPV]) and/or shock (with vasopressors) in a medical and/or surgical ICU at Vanderbilt University Medical Center enrolled in an ICU Delirium and Cognitive Impairment Study Group's clinical trials. Exclusion criteria for the parent studies are summarized below. No additional exclusion criteria are required for this investigation.

Exclusion Criteria:

• Expected death within 24 hours of enrollment or lack of commitment to aggressive treatment by family or the medical team (e.g., likely withdrawal of life support measures within 24 hours of screening)
• Active substance abuse, psychotic disorder, or homelessness without a secondary contact person (which would make long-term follow-up difficult)
• Blindness or deafness (which would prevent assessment of the study's outcomes)
• Inability to obtain informed consent

Related Conditions & MeSH terms

• Cognitive Impairment
• Critical Illness
• Delirium

Locations

Country	Name	City	State
United States	Vanderbilt University Medical Center	Nashville	Tennessee

Sponsors (2)

Lead Sponsor	Collaborator
Vanderbilt University Medical Center	DR. FRANZ KOHLER CHEMIE GMBH

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Activities of daily living	Katz Index of Independence in Activities of Daily Living	At 3, 6, and/or 12 months after hospital discharge up to 18 months after discharge
Other	Instrumental activities of daily living	Functional activities questionnaire	At 3, 6, and/or 12 months after hospital discharge up to 18 months after discharge
Other	Quality of life and generic health status	EQ-5D	At 3, 6, and/or 12 months after hospital discharge up to 18 months after discharge
Other	Coma	Richmond Agitation Sedation Scale	During hospital stay until death or hospital discharge, whichever comes first, up to 30 days
Primary	Delirium	Confusion Assessment Method for the ICU	During hospital stay until death or hospital discharge, whichever comes first, up to 30 days
Secondary	Global cognition	Neuropsychological battery	At 3, 6, and/or 12 months after hospital discharge up to 18 months after discharge